Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts EBIO Hot Sheet
Join SI Premium – FREE
Eleven Biotherapeutics (NASDAQ: EBIO) reported Q4 EPS of ($0.15), versus ($0.53) reported last year. Revenue for the quarter came in at $825 thousand, versus $565 thousand reported last year.
For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- DXP Enterprises (DXPE) Misses Q3 EPS by 1c
- Hudson Pacific Properties (HPP) Misses Q3 EPS by 265c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
